Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 23 entries
Sorted by: Best Match Show Resources per page
Targeted Therapy for BRAF Mutant Brain Tumors.

Current treatment options in oncology

Rayi A, Alnahhas I, Ong S, Giglio P, Puduvalli VK.
PMID: 34613491
Curr Treat Options Oncol. 2021 Oct 06;22(11):105. doi: 10.1007/s11864-021-00901-9.

OPINION STATEMENT: Molecular heterogeneity has confounded attempts to target individual pathways in brain tumors. However, gliomas with BRAF mutations have been identified as being uniquely vulnerable to targeted therapies. Such mutations are predominantly seen in brain tumors of the...

Cite
Rayi A, Alnahhas I, Ong S, et al. Targeted Therapy for BRAF Mutant Brain Tumors. Curr Treat Options Oncol. 2021;22(11):105doi: 10.1007/s11864-021-00901-9.
Rayi, A., Alnahhas, I., Ong, S., Giglio, P., & Puduvalli, V. K. (2021). Targeted Therapy for BRAF Mutant Brain Tumors. Current treatment options in oncology, 22(11), 105. https://doi.org/10.1007/s11864-021-00901-9
Rayi, Appaji, et al. "Targeted Therapy for BRAF Mutant Brain Tumors." Current treatment options in oncology vol. 22,11 (2021): 105. doi: https://doi.org/10.1007/s11864-021-00901-9
Rayi A, Alnahhas I, Ong S, Giglio P, Puduvalli VK. Targeted Therapy for BRAF Mutant Brain Tumors. Curr Treat Options Oncol. 2021 Oct 06;22(11):105. doi: 10.1007/s11864-021-00901-9. PMID: 34613491.
Copy Download .nbib Format: NLM
SNO 25th anniversary history series: Spotlight on Neuro-Oncology Practice and Neuro-Oncology Advances.

Neuro-oncology

Venere M, Zadeh G, Puduvalli V, Haynes C.
PMID: 32518956
Neuro Oncol. 2020 Jun 09;22(6):739-740. doi: 10.1093/neuonc/noaa108.

No abstract available.

Cite
Venere M, Zadeh G, Puduvalli V, et al. SNO 25th anniversary history series: Spotlight on Neuro-Oncology Practice and Neuro-Oncology Advances. Neuro Oncol. 2020;22(6):739-740doi: 10.1093/neuonc/noaa108.
Venere, M., Zadeh, G., Puduvalli, V., & Haynes, C. (2020). SNO 25th anniversary history series: Spotlight on Neuro-Oncology Practice and Neuro-Oncology Advances. Neuro-oncology, 22(6), 739-740. https://doi.org/10.1093/neuonc/noaa108
Venere, Monica, et al. "SNO 25th anniversary history series: Spotlight on Neuro-Oncology Practice and Neuro-Oncology Advances." Neuro-oncology vol. 22,6 (2020): 739-740. doi: https://doi.org/10.1093/neuonc/noaa108
Venere M, Zadeh G, Puduvalli V, Haynes C. SNO 25th anniversary history series: Spotlight on Neuro-Oncology Practice and Neuro-Oncology Advances. Neuro Oncol. 2020 Jun 09;22(6):739-740. doi: 10.1093/neuonc/noaa108. PMID: 32518956; PMCID: PMC7282891.
Copy Download .nbib Format: NLM
Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic.

Frontiers in oncology

Gatson NTN, Barnholtz-Sloan J, Drappatz J, Henriksson R, Hottinger AF, Hinoul P, Kruchko C, Puduvalli VK, Tran DD, Wong ET, Glas M.
PMID: 34026655
Front Oncol. 2021 May 07;11:679702. doi: 10.3389/fonc.2021.679702. eCollection 2021.

BACKGROUND: The COVID-19 pandemic has placed excessive strain on health care systems and is especially evident in treatment decision-making for cancer patients. Glioblastoma (GBM) patients are among the most vulnerable due to increased incidence in the elderly and the...

Cite
Gatson NTN, Barnholtz-Sloan J, Drappatz J, et al. Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. Front Oncol. 2021;11:679702doi: 10.3389/fonc.2021.679702.
Gatson, N. T. N., Barnholtz-Sloan, J., Drappatz, J., Henriksson, R., Hottinger, A. F., Hinoul, P., Kruchko, C., Puduvalli, V. K., Tran, D. D., Wong, E. T., & Glas, M. (2021). Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. Frontiers in oncology, 11679702. https://doi.org/10.3389/fonc.2021.679702
Gatson, Na Tosha N, et al. "Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic." Frontiers in oncology vol. 11 (2021): 679702. doi: https://doi.org/10.3389/fonc.2021.679702
Gatson NTN, Barnholtz-Sloan J, Drappatz J, Henriksson R, Hottinger AF, Hinoul P, Kruchko C, Puduvalli VK, Tran DD, Wong ET, Glas M. Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. Front Oncol. 2021 May 07;11:679702. doi: 10.3389/fonc.2021.679702. eCollection 2021. PMID: 34026655; PMCID: PMC8139188.
Copy Download .nbib Format: NLM
Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis.

Neuro-oncology advances

Alnahhas I, Alsawas M, Rayi A, Palmer JD, Raval R, Ong S, Giglio P, Murad MH, Puduvalli V.
PMID: 34258581
Neurooncol Adv. 2021 Jul 10;3(1):vdab095. doi: 10.1093/noajnl/vdab095. eCollection 2021.

[This corrects the article DOI: 10.1093/noajnl/vdaa082.].

Cite
Alnahhas I, Alsawas M, Rayi A, et al. Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis. Neurooncol Adv. 2021;3(1):vdab095doi: 10.1093/noajnl/vdab095.
Alnahhas, I., Alsawas, M., Rayi, A., Palmer, J. D., Raval, R., Ong, S., Giglio, P., Murad, M. H., & Puduvalli, V. (2021). Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis. Neuro-oncology advances, 3(1), vdab095. https://doi.org/10.1093/noajnl/vdab095
Alnahhas, Iyad, et al. "Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis." Neuro-oncology advances vol. 3,1 (2021): vdab095. doi: https://doi.org/10.1093/noajnl/vdab095
Alnahhas I, Alsawas M, Rayi A, Palmer JD, Raval R, Ong S, Giglio P, Murad MH, Puduvalli V. Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis. Neurooncol Adv. 2021 Jul 10;3(1):vdab095. doi: 10.1093/noajnl/vdab095. eCollection 2021. PMID: 34258581; PMCID: PMC8272530.
Copy Download .nbib Format: NLM
Prognostic implications of epidermal and platelet-derived growth factor receptor alterations in 2 cohorts of IDH.

Neuro-oncology advances

Alnahhas I, Rayi A, Guillermo Prieto Eibl MDP, Ong S, Giglio P, Puduvalli V.
PMID: 34667950
Neurooncol Adv. 2021 Oct 01;3(1):vdab127. doi: 10.1093/noajnl/vdab127. eCollection 2021.

BACKGROUND: Glioblastoma remains a deadly brain cancer with dismal prognosis. Genetic alterations, including METHODS: We compiled a comprehensive clinically annotated database of IDHwt GBM patients treated at the Ohio State University Wexner Medical Center for whom we had mutational...

Cite
Alnahhas I, Rayi A, Guillermo Prieto Eibl MDP, et al. Prognostic implications of epidermal and platelet-derived growth factor receptor alterations in 2 cohorts of IDH. Neurooncol Adv. 2021;3(1):vdab127doi: 10.1093/noajnl/vdab127.
Alnahhas, I., Rayi, A., Guillermo Prieto Eibl, M. D. P., Ong, S., Giglio, P., & Puduvalli, V. (2021). Prognostic implications of epidermal and platelet-derived growth factor receptor alterations in 2 cohorts of IDH. Neuro-oncology advances, 3(1), vdab127. https://doi.org/10.1093/noajnl/vdab127
Alnahhas, Iyad, et al. "Prognostic implications of epidermal and platelet-derived growth factor receptor alterations in 2 cohorts of IDH." Neuro-oncology advances vol. 3,1 (2021): vdab127. doi: https://doi.org/10.1093/noajnl/vdab127
Alnahhas I, Rayi A, Guillermo Prieto Eibl MDP, Ong S, Giglio P, Puduvalli V. Prognostic implications of epidermal and platelet-derived growth factor receptor alterations in 2 cohorts of IDH. Neurooncol Adv. 2021 Oct 01;3(1):vdab127. doi: 10.1093/noajnl/vdab127. eCollection 2021. PMID: 34667950; PMCID: PMC8519397.
Copy Download .nbib Format: NLM
Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma.

Neuro-oncology advances

Weathers SP, Rood-Breithaupt J, de Groot J, Thomas G, Manfrini M, Penas-Prado M, Puduvalli VK, Zwingelstein C, Yung WKA.
PMID: 34693288
Neurooncol Adv. 2021 Oct 02;3(1):vdab141. doi: 10.1093/noajnl/vdab141. eCollection 2021.

BACKGROUND: There is an urgent need for additional therapies to treat recurrent glioblastoma (GBM). Preclinical studies suggest that high dose macitentan, an oral dual endothelin receptor antagonist, enhances the cytotoxic effects of temozolomide (TMZ) in GBM, improving survival. This...

Cite
Weathers SP, Rood-Breithaupt J, de Groot J, et al. Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma. Neurooncol Adv. 2021;3(1):vdab141doi: 10.1093/noajnl/vdab141.
Weathers, S. P., Rood-Breithaupt, J., de Groot, J., Thomas, G., Manfrini, M., Penas-Prado, M., Puduvalli, V. K., Zwingelstein, C., & Yung, W. K. A. (2021). Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma. Neuro-oncology advances, 3(1), vdab141. https://doi.org/10.1093/noajnl/vdab141
Weathers, Shiao-Pei, et al. "Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma." Neuro-oncology advances vol. 3,1 (2021): vdab141. doi: https://doi.org/10.1093/noajnl/vdab141
Weathers SP, Rood-Breithaupt J, de Groot J, Thomas G, Manfrini M, Penas-Prado M, Puduvalli VK, Zwingelstein C, Yung WKA. Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma. Neurooncol Adv. 2021 Oct 02;3(1):vdab141. doi: 10.1093/noajnl/vdab141. eCollection 2021. PMID: 34693288; PMCID: PMC8528265.
Copy Download .nbib Format: NLM
Correction: Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity.

Disease models & mechanisms

Welker AM, Jaros BD, Puduvalli VK, Imitola J, Kaur B, Beattie CE.
PMID: 27604693
Dis Model Mech. 2016 Sep 01;9(9):1063-5. doi: 10.1242/dmm.027235.

No abstract available.

Cite
Welker AM, Jaros BD, Puduvalli VK, et al. Correction: Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity. Dis Model Mech. 2016;9(9):1063-5doi: 10.1242/dmm.027235.
Welker, A. M., Jaros, B. D., Puduvalli, V. K., Imitola, J., Kaur, B., & Beattie, C. E. (2016). Correction: Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity. Disease models & mechanisms, 9(9), 1063-5. https://doi.org/10.1242/dmm.027235
Welker, Alessandra M, et al. "Correction: Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity." Disease models & mechanisms vol. 9,9 (2016): 1063-5. doi: https://doi.org/10.1242/dmm.027235
Welker AM, Jaros BD, Puduvalli VK, Imitola J, Kaur B, Beattie CE. Correction: Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity. Dis Model Mech. 2016 Sep 01;9(9):1063-5. doi: 10.1242/dmm.027235. PMID: 27604693; PMCID: PMC5047695.
Copy Download .nbib Format: NLM
International patterns of palliative care in neuro-oncology: a survey of physician members of the Asian Society for Neuro-Oncology, the European Association of Neuro-Oncology, and the Society for Neuro-Oncology.

Neuro-oncology practice

Walbert T, Puduvalli VK, Taphoorn MJB, Taylor AR, Jalali R.
PMID: 31386064
Neurooncol Pract. 2015 Jun;2(2):62-69. doi: 10.1093/nop/npu037. Epub 2015 Feb 16.

BACKGROUND: Brain tumor patients have limited survival and suffer from high morbidity requiring specific symptom management. Specialized palliative care (PC) services have been developed to address these symptoms and provide end-of-life treatment. Global utilization patterns of PC in neuro-oncology...

Cite
Walbert T, Puduvalli VK, Taphoorn MJB, et al. International patterns of palliative care in neuro-oncology: a survey of physician members of the Asian Society for Neuro-Oncology, the European Association of Neuro-Oncology, and the Society for Neuro-Oncology. Neurooncol Pract. 2015;2(2):62-69doi: 10.1093/nop/npu037.
Walbert, T., Puduvalli, V. K., Taphoorn, M. J. B., Taylor, A. R., & Jalali, R. (2015). International patterns of palliative care in neuro-oncology: a survey of physician members of the Asian Society for Neuro-Oncology, the European Association of Neuro-Oncology, and the Society for Neuro-Oncology. Neuro-oncology practice, 2(2), 62-69. https://doi.org/10.1093/nop/npu037
Walbert, Tobias, et al. "International patterns of palliative care in neuro-oncology: a survey of physician members of the Asian Society for Neuro-Oncology, the European Association of Neuro-Oncology, and the Society for Neuro-Oncology." Neuro-oncology practice vol. 2,2 (2015): 62-69. doi: https://doi.org/10.1093/nop/npu037
Walbert T, Puduvalli VK, Taphoorn MJB, Taylor AR, Jalali R. International patterns of palliative care in neuro-oncology: a survey of physician members of the Asian Society for Neuro-Oncology, the European Association of Neuro-Oncology, and the Society for Neuro-Oncology. Neurooncol Pract. 2015 Jun;2(2):62-69. doi: 10.1093/nop/npu037. Epub 2015 Feb 16. PMID: 31386064; PMCID: PMC6668255.
Copy Download .nbib Format: NLM
The Society for Neuro-Oncology: 20/20 vision for the future.

Neuro-oncology

Venere M, Zadeh G, Puduvalli V, Haynes C.
PMID: 32095809
Neuro Oncol. 2020 Apr 15;22(4):435-436. doi: 10.1093/neuonc/noaa043.

No abstract available.

Cite
Venere M, Zadeh G, Puduvalli V, et al. The Society for Neuro-Oncology: 20/20 vision for the future. Neuro Oncol. 2020;22(4):435-436doi: 10.1093/neuonc/noaa043.
Venere, M., Zadeh, G., Puduvalli, V., & Haynes, C. (2020). The Society for Neuro-Oncology: 20/20 vision for the future. Neuro-oncology, 22(4), 435-436. https://doi.org/10.1093/neuonc/noaa043
Venere, Monica, et al. "The Society for Neuro-Oncology: 20/20 vision for the future." Neuro-oncology vol. 22,4 (2020): 435-436. doi: https://doi.org/10.1093/neuonc/noaa043
Venere M, Zadeh G, Puduvalli V, Haynes C. The Society for Neuro-Oncology: 20/20 vision for the future. Neuro Oncol. 2020 Apr 15;22(4):435-436. doi: 10.1093/neuonc/noaa043. PMID: 32095809; PMCID: PMC7158644.
Copy Download .nbib Format: NLM
High-dose methotrexate-based regimens with or without vincristine for the treatment of primary central nervous system lymphoma.

Neuro-oncology advances

Freeman T, Legasto CS, Schickli MA, McLaughlin EM, Giglio P, Puduvalli V, Gonzalez J.
PMID: 32715297
Neurooncol Adv. 2020 Jun 29;2(1):vdaa077. doi: 10.1093/noajnl/vdaa077. eCollection 2020.

BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a rare malignancy with few treatment options. One regimen used for induction is rituximab, high-dose methotrexate (HD-MTX), procarbazine, and vincristine (R-MPV). A common institutional practice is removing vincristine (VCR) from this...

Cite
Freeman T, Legasto CS, Schickli MA, et al. High-dose methotrexate-based regimens with or without vincristine for the treatment of primary central nervous system lymphoma. Neurooncol Adv. 2020;2(1):vdaa077doi: 10.1093/noajnl/vdaa077.
Freeman, T., Legasto, C. S., Schickli, M. A., McLaughlin, E. M., Giglio, P., Puduvalli, V., & Gonzalez, J. (2020). High-dose methotrexate-based regimens with or without vincristine for the treatment of primary central nervous system lymphoma. Neuro-oncology advances, 2(1), vdaa077. https://doi.org/10.1093/noajnl/vdaa077
Freeman, Tracelyn, et al. "High-dose methotrexate-based regimens with or without vincristine for the treatment of primary central nervous system lymphoma." Neuro-oncology advances vol. 2,1 (2020): vdaa077. doi: https://doi.org/10.1093/noajnl/vdaa077
Freeman T, Legasto CS, Schickli MA, McLaughlin EM, Giglio P, Puduvalli V, Gonzalez J. High-dose methotrexate-based regimens with or without vincristine for the treatment of primary central nervous system lymphoma. Neurooncol Adv. 2020 Jun 29;2(1):vdaa077. doi: 10.1093/noajnl/vdaa077. eCollection 2020. PMID: 32715297; PMCID: PMC7372924.
Copy Download .nbib Format: NLM
Inhibition of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the nicotinamide adenine dinucleotide salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.

Neuro-oncology

Sharma P, Xu J, Williams K, Easley M, Elder JB, Lonser R, Lang FF, Lapalombella R, Sampath D, Puduvalli VK.
PMID: 34260721
Neuro Oncol. 2021 Jul 14; doi: 10.1093/neuonc/noab175. Epub 2021 Jul 14.

BACKGROUND: Tumor-specific metabolic processes essential for cell survival are promising targets to potentially circumvent intratumoral heterogeneity, a major resistance factor in gliomas. Tumor cells preferentially using nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the salvage pathway for synthesis of...

Cite
Sharma P, Xu J, Williams K, et al. Inhibition of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the nicotinamide adenine dinucleotide salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. Neuro Oncol. 2021;doi: 10.1093/neuonc/noab175.
Sharma, P., Xu, J., Williams, K., Easley, M., Elder, J. B., Lonser, R., Lang, F. F., Lapalombella, R., Sampath, D., & Puduvalli, V. K. (2021). Inhibition of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the nicotinamide adenine dinucleotide salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. Neuro-oncology, . https://doi.org/10.1093/neuonc/noab175
Sharma, Pratibha, et al. "Inhibition of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the nicotinamide adenine dinucleotide salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress." Neuro-oncology vol. (2021). doi: https://doi.org/10.1093/neuonc/noab175
Sharma P, Xu J, Williams K, Easley M, Elder JB, Lonser R, Lang FF, Lapalombella R, Sampath D, Puduvalli VK. Inhibition of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the nicotinamide adenine dinucleotide salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. Neuro Oncol. 2021 Jul 14; doi: 10.1093/neuonc/noab175. Epub 2021 Jul 14. PMID: 34260721.
Copy Download .nbib Format: NLM
Assessment of Leptomeningeal Carcinomatosis Diagnosis, Management and Outcomes in Patients with Solid Tumors Over a Decade of Experience.

European journal of breast health

Rinehardt H, Kassem M, Morgan E, Palettas M, Stephens JA, Suresh A, Ganju A, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Cherian M, Prieto Eibl MDPG, Miah A, Alnahhas I, Giglio P, Puduvalli VK, Ramaswamy B, Williams N, Noonan AM.
PMID: 34651117
Eur J Breast Health. 2021 Oct 04;17(4):371-377. doi: 10.4274/ejbh.galenos.2021.2021-4-10. eCollection 2021 Oct.

OBJECTIVE: Leptomeningeal carcinomatosis (LMC), a common complication of advanced malignancies, is associated with high morbidity and mortality, yet diagnosis and treatment decisions remain challenging. This study describes the diagnostic and treatment modalities for LMC and identifies factors associated with...

Cite
Rinehardt H, Kassem M, Morgan E, et al. Assessment of Leptomeningeal Carcinomatosis Diagnosis, Management and Outcomes in Patients with Solid Tumors Over a Decade of Experience. Eur J Breast Health. 2021;17(4):371-377doi: 10.4274/ejbh.galenos.2021.2021-4-10.
Rinehardt, H., Kassem, M., Morgan, E., Palettas, M., Stephens, J. A., Suresh, A., Ganju, A., Lustberg, M., Wesolowski, R., Sardesai, S., Stover, D., Vandeusen, J., Cherian, M., Prieto Eibl, M. D. P. G., Miah, A., Alnahhas, I., Giglio, P., Puduvalli, V. K., Ramaswamy, B., Williams, N., & Noonan, A. M. (2021). Assessment of Leptomeningeal Carcinomatosis Diagnosis, Management and Outcomes in Patients with Solid Tumors Over a Decade of Experience. European journal of breast health, 17(4), 371-377. https://doi.org/10.4274/ejbh.galenos.2021.2021-4-10
Rinehardt, Hannah, et al. "Assessment of Leptomeningeal Carcinomatosis Diagnosis, Management and Outcomes in Patients with Solid Tumors Over a Decade of Experience." European journal of breast health vol. 17,4 (2021): 371-377. doi: https://doi.org/10.4274/ejbh.galenos.2021.2021-4-10
Rinehardt H, Kassem M, Morgan E, Palettas M, Stephens JA, Suresh A, Ganju A, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Cherian M, Prieto Eibl MDPG, Miah A, Alnahhas I, Giglio P, Puduvalli VK, Ramaswamy B, Williams N, Noonan AM. Assessment of Leptomeningeal Carcinomatosis Diagnosis, Management and Outcomes in Patients with Solid Tumors Over a Decade of Experience. Eur J Breast Health. 2021 Oct 04;17(4):371-377. doi: 10.4274/ejbh.galenos.2021.2021-4-10. eCollection 2021 Oct. PMID: 34651117; PMCID: PMC8496125.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 23 entries